Portal Diabetes

Portal Diabetes is a medical technology company developing the world's first fully automated, implantable artificial pancreas system. Its flagship technology, the Portal Pump (formerly known as ThinPump), utilizes intraperitoneal insulin delivery to mimic the natural physiological function of the liver, providing significantly faster pharmacokinetics than traditional subcutaneous pumps. The system is designed to eliminate the daily burdens of diabetes management, such as carbohydrate counting, meal announcements, and manual bolusing, while aiming for over 90% time-in-range for patients. Headquartered in Westfield, Indiana, the company is currently advancing its platform through clinical stages to provide a functional cure for Type 1 Diabetes.